Puma Biotech (PBYI) Tops Q4 EPS by 95c, Beat on Revenues

Note: EPS may not be comparable

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($1.03), $0.95 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.01 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• The LGL Group (LGL) Misses Q2 EPS by 8c